Latest News

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease





OSAKA, Japan–(BUSINESS WIRE)–Takeda acquired PvP Biologics following a Phase 1 study of investigational medicine TAK-062 for the treatment of uncontrolled celiac disease.

Source link




Related posts

Is Medical Pot a Blessing for Seniors?

Newsemia

Listen: Pharma’s response to coronavirus, Google’s appetite for health data, and biotech’s rise in China

Newsemia

Stereotypes About Girls and Math Don't Add Up, Scans Show

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy